Other Name: interleukin 2 (IL-2)

Inleusin is a recombinant human interleukin 2 (IL-2) product that is structurally and functionally similar to naturally produced IL-2, an immune regulator. IL-2 is a natural part of the human immune response to microbial infection. IL-2 promotes the proliferation and maturation of, among others, T-cells and natural killer cells, both of which are capable of destroying cancer cells directly. Inleusin is indicated for treatment of renal cell carcinoma, melanoma, thoracic fluid build-up caused by cancer, and tuberculosis.

We obtained CFDA approval to manufacture and market Inleusin in the PRC market in June 1995 and launched the product in March 1996. It was one of the first interleukin products introduced in the PRC market. Inleusin is manufactured at our bacterial cell-based production plant in Shenyang. Our Inleusin products are available in four dosages: 0.1 MIU, 0.2 MIU, 0.5 MIU and 1 MIU. Inleusin is included in the National Medical Insurance Catalogue as a Category B drug.